Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 2;7(12):e2451813.
doi: 10.1001/jamanetworkopen.2024.51813.

Universal Health Checkups and Risk of Incident Diabetes and Hypertension

Affiliations

Universal Health Checkups and Risk of Incident Diabetes and Hypertension

Masato Takeuchi et al. JAMA Netw Open. .

Abstract

Importance: Type 2 diabetes and hypertension are obesity-related, noncommunicable diseases becoming increasingly common worldwide. In 2008, Japan launched a nationwide universal health checkup program, Specific Health Checkup (SHC), for the primary prevention of obesity-related diseases, but its effectiveness has been understudied.

Objective: To investigate the association of the SHC program with incident diabetes and hypertension, using a target trial emulation framework.

Design, setting, and participants: This retrospective cohort study used data from a longitudinal health care database involving both checkup history and medical encounter records in Japan. Individuals aged 40 to 74 years, without diabetes or hypertension, and without a prior checkup history, were eligible. Individuals were repeatedly assessed for eligibility from April 1, 2008, to March 31, 2020, to assemble sequential cohorts of 78 620 SHC participants and 214 554 nonparticipants. Statistical analysis was conducted from June 8 to December 30, 2023.

Main outcomes and measures: The composite risk of incident type 2 diabetes or hypertension over a period of up to 10 years, defined as the combination of a newly documented diagnosis and use of relevant medications. A propensity score-weighted survival analysis was conducted to adjust for baseline variables. A series of sensitivity analyses and a negative outcome control analysis were conducted using depression as a benchmark.

Results: Sequential cohorts consisted of 78 620 SHC participants (median age, 46 years [IQR, 41-53 years]; 62.7% women) and 214 554 nonparticipants (median age, 49 years [IQR, 44-55 years]; 82.0% women) from 153 084 unique persons, each of whom entered the study cohort a mean (SD) of 1.9 (1.5) times. Within a median follow-up of 4.2 years (IQR, 2.7-6.3 years), the primary end point occurred among 11.2% of all individuals (10.6% of the SHC participants and 11.4% of the nonparticipants), with a lower hazard ratio (HR) among the SHC recipients (HR, 0.90; 95% CI, 0.89-0.92); the difference in cumulative incidence at 10 years was -1.6% (95% CI, -1.8% to -1.3%). The sensitivity analyses showed similar results. The negative control analysis suggested the potential for residual confounding (HR, 1.05; 95% CI, 1.02-1.07); the bias-calibrated HR was 0.86 (95% CI, 0.84-0.89) for the primary outcome.

Conclusions and relevance: In this cohort study, within a median of 4.2 years of follow-up, SHC recipients had a 9.8% lower risk of incident diabetes and hypertension (13.8% in the bias-calibrated analysis). The cost-effectiveness of the SHC and its transportability to other regions are unclear, requiring future investigations.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Takeuchi reported receiving personal fees from Eisai Co Ltd during the conduct of the study. Dr Shinozaki reported receiving personal fees from Pfizer Japan Inc, Novartis Pharma KK, and SAS Institute Japan Inc outside the submitted work. Dr Kawakami reported receiving personal fees from JMDC during the conduct of the study; grants from Eisai Co Ltd, Kyowa Kirin Co Ltd, Omron Corp, and Toppan Inc; personal fees from Advanced Medical Care, Shin Nippon Biomedical Laboratories Ltd, Cancer Intelligence Care Systems Inc, Chugai Pharmaceutical Co Ltd, Pharma Business Academy, Toppan Inc, and Real World Data Co Ltd outside the submitted work. No other disclosures were reported.

Figures

Figure 1.
Figure 1.. Flowchart of the Study Cohort
aSHC indicates Specific Health Checkup. aAge between 40 and 74 years, no checkup history, and data lookback period of at least 12 months. bOne participant may fulfill several exclusion criteria. cProxies for physically handicapped individuals or nursing home residents, defined as those within the upper 99.99th percentile of resource use (outpatient visits and/or admission services).
Figure 2.
Figure 2.. Crude Disease-Free Probability for Type 2 Diabetes and Hypertension
Inset, survival curve in years. SHC indicates Specific Health Checkup.
Figure 3.
Figure 3.. Disease-Free Survival Probability in the Population Adjusted by Inverse Probability Weighting
Inset, survival curve in years. SHC, indicates Specific Health Check.

References

    1. Nyberg ST, Batty GD, Pentti J, et al. . Obesity and loss of disease-free years owing to major non-communicable diseases: a multicohort study. Lancet Public Health. 2018;3(10):e490-e497. doi:10.1016/S2468-2667(18)30139-7 - DOI - PMC - PubMed
    1. Kivimäki M, Strandberg T, Pentti J, et al. . Body-mass index and risk of obesity-related complex multimorbidity: an observational multicohort study. Lancet Diabetes Endocrinol. 2022;10(4):253-263. doi:10.1016/S2213-8587(22)00033-X - DOI - PMC - PubMed
    1. Saluja K, Reddy KS, Wang Q, et al. . Improving WHO’s understanding of WHO guideline uptake and use in member states: a scoping review. Health Res Policy Syst. 2022;20(1):98. doi:10.1186/s12961-022-00899-y - DOI - PMC - PubMed
    1. Tuomilehto J, Uusitupa M, Gregg EW, Lindström J. Type 2 diabetes prevention programs-from proof-of-concept trials to national intervention and beyond. J Clin Med. 2023;12(5):1876. doi:10.3390/jcm12051876 - DOI - PMC - PubMed
    1. Ministry of Health, Labour and Welfare, Japan . Specific health checkups and specific health guidance. Accessed January 25, 2024. https://www.mhlw.go.jp/english/wp/wp-hw3/dl/2-007.pdf

Publication types